I'm LongbridgeAI, I can summarize articles.Aldeyra Therapeutics reported a narrowed GAAP net loss of $5.45 million for Q2 2026, down 44.2% from the prior year. Operating losses decreased by 42.5% to $5.85 million, driven by a 59% drop in R&D expenses. The company holds $45.1 million in cash and expects funding into late 2028. Additionally, AbbVie has not exercised its reproxalap option, and Aldeyra repaid its $15 million Hercules loan in April.
- Aldeyra Therapeutics posted a GAAP net loss of USD 5.45 million for Q2 2026, narrowing 44.2% from a loss of USD 9.77 million. * Operating loss improved 42.5% to USD 5.85 million, as research and development expense fell 59% to USD 3.48 million. * General and administrative expense rose 42.2% to USD 2.37 million, while interest income dropped 54.1% to USD 400,257. * Cash and cash equivalents totaled USD 45.1 million at June 30, 2026; the company said it expects funding into the second half of 2028. * AbbVie has not exercised its reproxalap option as of Aug. 6, 2026; Aldeyra repaid its USD 15 million Hercules loan on April 1, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001341235-26-000010), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here